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Abstract: Growing evidence supports the pivotal role played by oxidative stress in tissue injury
development, thus resulting in several pathologies including cardiovascular, renal, neuropsychiatric,
and neurodegenerative disorders, all characterized by an altered oxidative status. Reactive oxygen
and nitrogen species and lipid peroxidation-derived reactive aldehydes including acrolein,
malondialdehyde, and 4-hydroxy-2-nonenal, among others, are the main responsible for cellular
and tissue damages occurring in redox-dependent processes. In this scenario, a link between
the endocannabinoid system (ECS) and redox homeostasis impairment appears to be crucial.
Anandamide and 2-arachidonoylglycerol, the best characterized endocannabinoids, are able to
modulate the activity of several antioxidant enzymes through targeting the cannabinoid receptors
type 1 and 2 as well as additional receptors such as the transient receptor potential vanilloid 1,
the peroxisome proliferator-activated receptor alpha, and the orphan G protein-coupled receptors 18
and 55. Moreover, the endocannabinoids lipid analogues N-acylethanolamines showed to protect cell
damage and death from reactive aldehydes-induced oxidative stress by restoring the intracellular
oxidants-antioxidants balance. In this review, we will provide a better understanding of the main
mechanisms triggered by the cross-talk between the oxidative stress and the ECS, focusing also on
the enzymatic and non-enzymatic antioxidants as scavengers of reactive aldehydes and their toxic
bioactive adducts.
Keywords: oxidative stress; lipid peroxidation; reactive aldehydes; reactive oxygen and nitrogen
species; free radicals; endocannabinoids; cannabinoid receptors; peroxisome proliferator-activated
receptors; transient receptor potential vanilloid; G protein-coupled receptors
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1. Introduction
Oxidative stress and lipid peroxidation are the consequences of a deregulated redox homeostasis
that results in the accumulation of highly reactive molecules and cellular injury, especially in
those tissues with a high oxygen consumption, such as heart, kidney, and brain, thus leading to
cardiovascular [1,2], renal [3], and neurodegenerative diseases [4–6], just to mention a few. Examples of
the possible repercussions of free radical damage are provided in this review with special emphasis on
lipid peroxidation-derived reactive aldehydes including acrolein (ACR), malondialdehyde (MDA),
and 4-hydroxy-2-nonenal (4-HNE), among others [7].
To get a deeper insight into the cellular pathways that regulate reactive oxygen and nitrogen
species (ROS/RNS) as well as reactive aldehydes formation, there is a growing interest in identifying
free radical scavenging molecules that can prevent cell death following oxidative stress-induced
damage of cellular membranes. In this perspective, over the last few years, the endocannabinoid system
(ECS) has attracted significant attention because of the existing cross-talk between endocannabinoids
(ECs) as well as their lipid analogues and various redox-dependent processes. Therefore, the pathways
by which the ECs and their lipid-related mediators contribute to the modulation of oxidative stress and
lipid peroxidation represent a significant research area that will yield novel pharmaceutical strategies
for the treatment of diseases characterized by a redox imbalance.
The cannabinoid receptors type 1 (CB1) and 2 (CB2), together with additional ECs receptor targets,
take part in the complex ECS and, because of their wide distribution, they may play a role in mediating
the antioxidant properties of ECs [8–10]. However, the great diversity of results in this field discloses
the requirement of a better understanding on the pathways by which these receptors are involved in
regulating oxidative stress and lipid peroxidation processes.
In this review, we will provide an overview of the role of the ECS in pathological conditions
related to a redox status imbalance, leading to a better comprehension of the intricate routes that are
associated to the antioxidant properties exerted by the ECs, thus enhancing the research in finding a
therapeutic benefit for cannabinoid-based drugs in various redox-dependent disorders.
2. Oxidative Stress and Lipid Peroxidation
Oxidative stress can be described as an imbalance between the production of oxidant species and
the antioxidant defenses, which may affect cellular redox homeostasis leading to molecular alterations
and thus resulting in cell and tissue damage [11]. The term “oxidants” is a general term used to identify
several groups of reactive molecules among which ROS and RNS are considered the most interesting
from a biological point of view. ROS/RNS are natural byproducts of aerobic metabolism and are
produced by all living multicellular organisms. ROS include free oxygen radicals and non-radical
molecules, such as superoxide anion (O2•−), hydroxyl (•OH), peroxyl, alkyl, and alkoxyl radicals,
as well as singlet oxygen (1O2), hydrogen peroxide (H2O2), ozone (O3), and hypochlorous acid
(HClO), while RNS include nitrogen compounds such as nitric oxide (•NO), nitrogen dioxide (NO2•),
nitrate (NO3−), nitrite (NO2−), and peroxynitrite (ONOO−) [12,13].
In mammals, the main cellular sources of ROS/RNS are the mitochondrial and microsomal
electron transport chains [14], the NADPH oxidase enzymes (NOXs), which consist of seven isoforms
with various tissue distributions and mechanisms of activation [15,16], the flavoenzyme endoplasmic
reticulum oxireductin 1 [17], nitric oxide synthase (NOS) [18], cytochrome P450 enzymes [19],
cyclooxygenases (COXs), lipoxygenases (LOXs) [20], xanthine oxidase [21], diamine oxidase [22],
and prostaglandin synthase [23]. In addition to these endogenous sources, the ionizing radiation,
ultraviolet rays, pathogens, xenobiotics (e.g., drugs, herbicides, fungicides, trace metals, etc.),
and environmental pollutants (e.g., smog, cigarette smoke, smoke from wood combustion, etc.)
are identified as exogenous sources of ROS/RNS [24], which may seriously alter the fundamental
oxidants-antioxidants balance.
To date, growing evidence confirms that ROS/RNS are produced by healthy cells in a highly
regulated fashion in order to maintain the intracellular redox homeostasis. Moreover, ROS/RNS
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regulate several cellular functions ranging from immune defense to gene expression regulation,
thus acting as reactive molecules secreted against circulating pathogens [25] or as second messengers
of specific signaling pathways [26]. The crucial role played by ROS/RNS in immune defense was
demonstrated by the discovery of the chronic granulomatous disorder (CGD), a hereditary disease
characterized by NOX type 2 (NOX2)-defective phagocytes [27] which are unable to produce ROS/RNS.
This genetic defect leads CGD patients in developing a primary immunodeficiency due to the inability
of host innate defense to kill and digest ingested pathogens such as bacterial and fungal cells [28–31].
Moreover, ROS/RNS play also an important role in the cardiovascular system because of their
ability to regulate blood pressure. In particular, the endothelial NOX2 isoform regulates the release
of •NO, the endothelium-derived relaxing factor, which modulates the caliber of blood vessels,
through the production of O2•−. In hypertension and other vascular pathologies, NOX2 seems to be
up-regulated leading to a reduced •NO bioavailability and to the consequent oxidants-antioxidants
imbalance in the endothelium, further worsening the oxidative state [32–34]. Moreover, in vivo
studies of single nephron function and in vitro studies performed on perfused juxtaglomerular
apparatus preparation demonstrated that also the normal renal functions are modulated by ROS/RNS.
In particular, O2•− and •NO, which are generated by NOX type 3 (NOX3) and NOS type 1 (NOS1)
enzymes, respectively, modulate afferent arteriolar tone and control Na+ reabsorption and renal
oxygenation by regulating the tubuloglomerular feedback response [35–37]. Furthermore, in the loop
of Henle, ROS/RNS increase the absorption of NaCl by modulating the activity of the Na+/H+
exchanger [38,39]. In airway and pulmonary artery smooth muscle cells of the lung, NOX2-generated
ROS/RNS act as signaling intermediates, which regulate the proliferation and differentiation by
the activation of the nuclear factor-κB (NF-κB) and NOS2, and they further show an important role in
O2 sensing [39–41].
Moreover, ROS/RNS formation by mucosal cells of the colon seems to modulate the serotonin
production by enterochromaffin cells through a NOXs-dependent system, thus contributing to
the regulation of serotonin secretion as well as intestinal motility [42]. ROS/RNS have also
a fundamental role in the central nervous system (CNS), in particular in central autonomic
neurons. To this regard, ROS/RNS produced by NOX2 in the nucleus of the solitary tract,
in the hypothalamic paraventricular nucleus, and in the subfornical organ modulate angiotensin
II signaling, thus contributing to the regulation of cardiovascular homeostasis [43,44]. Moreover,
in microglia but not in astrocytes, H2O2 formation by NOX2 enzyme is involved in the regulation of
cell proliferation [45].
Beyond the role as signaling molecules, it has been shown that the aberrant ROS/RNS formation
is the leading cause of cell and tissue oxidative stress-induced damage. Indeed, it is well known that
excessive levels of ROS/RNS may directly damage lipids containing carbon-carbon double bounds
such as cholesterol, glycolipids, phospholipids, and polyunsatured fatty acids (PUFAs), which are
abundant within cellular membranes. To this regard, free radical–mediated lipid peroxidation of PUFAs
is one of the main mechanisms by which ROS/RNS induce the generation of reactive aldehydes [46].
Due to their abundance of reactive hydrogens, PUFAs are more oxidation-prone lipids compared to
monounsatured fatty acids. PUFAs include the ω-3 (e.g., linolenic acid, eicosapentaenoic acid and
docosahexaenoic acid) andω-6 (e.g., linoleic acid and arachidonic acids) fatty acids.
Lipid peroxidation is a chain reaction, which, once started, proceeds through three main
steps referred to initiation, propagation and termination [47]. Moreover, lipid peroxidation may
occur by several mechanisms: (1) free radical-mediated oxidation [47], (2) enzymatic oxidation,
and (3) spontaneous oxidation [48]. In this review, we will focus mainly on the free radical–mediated
mechanisms that lead to the formation of reactive aldehydes from PUFAs. In particular, the free
radical-mediated oxidation of PUFAs occurs through the following reactions: (1) During the initiation
phase, ROS/RNS free radicals attack PUFAs ripping off one hydrogen atom, leading to lipid
radicals formation. (2) During the propagation phase, lipid radicals react with oxygen molecules,
thus producing peroxyl radicals, which, in turn, react with nearby lipids resulting in the formation of
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new lipid radicals and lipid hydroperoxides. Due to their high instability, lipid hydroperoxides are
further degraded into reactive secondary products, such as ACR, MDA, 4-HNE and other reactive
aldehydes [7]. (3) During the termination phase, peroxyl radicals may react with other radicals thus
generating less reactive compounds, which block the propagation phase (Figure 1) [49].
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Figure 1. Sche atic diagra of the free radicals- ediated peroxidation of polyunsatured fatty acids
( F s). S R S: reactive oxyge a itroge s ecies; : acrolei ; : alo ial e y e;
: crotonaldehyde; 4-HNE: 4-hydroxy-2-nonenal; 4-HHE: 4-hydrox -hexanal; 4-ONE: 4-oxo-nonenal.
During the initiation phase (1), ROS/RNS free radicals react with PUFAs and rip off an allylic hydrogen
thus forming lipid radicals. Generally, lipid radicals tend to be stabilized by a molecular rearrang ment.
(2) In the propagatio phase, lipid radicals r act with oxygen to form lipid p roxyl radicals, which in
turn react wit PUFAs or other nearby lipids resulting in the formatio of new lipid radicals an
lipid hydroperoxides (3). During the termination phase (4), antioxida ts or lipid adicals block
the propagation phase by donating a hydrogen atom to lipid peroxyl radicals resulting in the formation
of non-radical products. Nevertheless, lipid hydroperoxi es a e highly unstab e therefore they a
furthe degraded into r active s condary pro ucts such as ACR, MDA, 4-HNE, and other reac ive
aldehydes (5).
Today, it is well accepted that oxidative stress and lipid peroxidation are key features in
the pathogenesis of several disorders. Indeed, it has been reported that lipid peroxidation products
may interfere in vivo with several biological processes, such as substrate-receptor interaction,
signal transduction, gene expression, and homeostatic responses to intracellular and environmental
stimuli [50–53]. Currently, the main objective of research focused on oxidative stress, lipid peroxidation,
and reactive aldehydes is the characterization of the pathogenic mechanisms in several disorders as
well as the identification of specific biomarkers for diseases.
Among the reactive aldehydes, the most frequently studied are ACR, MDA, 4-HNE, 4-hydroxy-
hexanal (4-HHE), 4-oxo-nonenal (4-ONE), and crotonaldehyde (CTA) (Figure 2).
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ACR: acrolein; MDA: malondialdehyde; CTA: crotonaldehyde; 4-HNE: 4-hydroxy-2-nonenal; 4-HHE:
4-hydroxy-hexanal; 4-ONE: 4-oxo-nonenal.
Some of t s are known to contribute to the pathogenesis of several diseases,
such as atherosclerosis, rheumatoid arthritis, neuropsychiatric disorders, eart is , cellular
reperfusion injury, cancer, and metabolic disorders such as diabetes and hepatic diseases [4,5,7,12,54].
Reactive aldehydes r f electrophilic molecules with different features: some of them
ar very unstable, characterized by a short half-life, while others are long-lived and highly reactive.
In the past years, the endogenous formati n of reactive aldehyde has drawn great interest. The
ability of aldehydes to easily diffuse across biological membranes [55], and to f a cts with
macromolecules uch as phospholipids, nucleic acids an proteins [7,46,56–58], is of particular concern.
Adducts consist of valent m difications, which involve the f rmation f Schiff bases or Michael
addition reactions. To this regard, t e reactive ald hydes toxicity against peptides and proteins is due
to their ability to alter their structur and/or f nction through the formation of cross-links between
different amino acid chains, thus potenti lly leading to the production of aberrant protei aggregates
(Figure 3) [59]. Concerning the toxicity of reactiv aldehydes against DNA, it has been shown that
th se compounds may react agai st nucleob ses, among which th most affected is guanine, du to its
chemical str cture prone to oxidative modifications. The most studied DNA modifications caused by
reactive ldehydes are the xocyclic adducts (Figur 4) [57,58,60].
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Figure 3. Schematic representation of protein adducts formation and protein-protein cross-linking by
4-HNE. Reactive aldehydes are able to modify peptides/proteins by the formation of toxic adducts
which may alter the structure and/or the function of targeted peptides/proteins. These adducts consist
of covalent modifications which occur through the formation of Schiff bases or through Michael addition
reactions: (1) Schiff base formation on primary amine (lysine residue) through the reaction between
peptides/proteins and 4-HNE, (2) Michael addition of 4-HNE on amino groups (lysine/histidine
residues) or thiols (cysteine residue) through the reaction between peptides/proteins and 4-HNE,
and (3) Protein-protein cross-linking through the reaction between 4-HNE with histidine and lysine
residues from different peptides/proteins.
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Figure 4. Hypothetical DNA adducts produced by reactive aldehydes.By reacting with DNA,
in particular with the deoxyguanosine nucleobases, several reactive aldehydes such as ACR, MDA,
4-HNE, 4-ONE and CTA produce DNA modifications named exocyclic adducts that alter the DNA
structure and, if not correctly repaired, may produce carcinogenic effects.
4-HNE and 4-ONE are generated from lipid peroxidation ofω-6 PUFAs (e.g., arachidonic acid
and linoleic acid) [61]. Among reactive aldehydes, 4-HNE is the most studied, and its toxic effects
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can be explained by its ability to form protein adducts by reacting with thiols and amino groups
of cysteine, histidine, and lysine amino acid residues [62]. For a detailed explanation of the main
4-HNE-modified proteins, see the following publication [63]. 4-ONE is an electrophilic compound
that reacts both in vitro and in vivo with nucleobases, in particular with 2′-deoxyadenosine and
2′-deoxycytidine [64–67].
Unlike 4-HNE and 4-ONE, 4-HHE is generated from ω-3 PUFAs (e.g., docoshexaenoic acid,
eicosapentaenoic acid and linolenic acid) and, because of its chemical structure, it is considered a soft
electrophil with a lower reactivity compared to 4-HNE [7].
MDA, which is widely used as a marker of lipid peroxidation [68], contains at least two
unsaturations [7] and is generally produced by PUFAs. Regarding its toxicity, MDA modifies target
proteins through the formation of Schiff base complexes, which occur on the amino groups of lysine,
histidine, arginine, glutamine, and asparagine amino acid residues as well as on the N-terminal of
peptide chains [69]. For a detailed explanation of the main MDA-modified proteins, see the following
publication [63]. Moreover, in vitro mutagenicity of MDA has been observed by several authors using
the Salmonella tiphimurium assay [70–72]. Several studies showed the presence of both MDA and
MDA-protein adducts in rheumatoid arthritis patients compared to healthy controls [73–76]. Moreover,
high levels of circulating autoantibodies against MDA-modified epitopes have been detected in serum
or plasma of patients affected by rheumatoid arthritis [77–79]. CTA or 2-butenal is a carcinogenic
aldehyde formed by lipid peroxidation, which is also commonly found in air pollution, in cigarette
smoke and in other combustion processes. CTA is able to form adducts with DNA [80–83] and proteins.
In accordance with in vitro mutagenesis assay with Salmonella typhimorium, CTA is a mutagenic
compound [84] able to induce hepatocellular carcinoma in rats [85]. About protein modifications,
CTA reacts preferentially with lysine and histidine amino acid residues, thus forming β-substituted
butanal adducts [86].
ACR or propenal is a metabolite of PUFAs lipid peroxidation, but it is also a ubiquitous environmental
pollutant by-product derived by incomplete combustion of organic matter and plastic, cigarette smoke,
overheated cooking oils, as well as by anticancer treatment with cyclophosphamide [87,88]. Among
reactive aldehydes, ACR is the strongest electrophile, which shows a high reactivity with cysteine,
histidine, and lysine amino acid residues. Moreover, ACR forms cyclic adducts with nucleosides
in vitro, and is recognized as a potent mutagen [89].
Despite their harmful properties, growing evidence has also demonstrated the hormetic
effects of reactive aldehydes [51,63,90–93]. The term “hormesis” refers to a highly conserved and
dose-dependent response of biological systems in which low doses of noxious stimuli activate an
adaptive response that increases the functionality and/or resistance of the systems to more severe
stress. Conversely, high doses of noxious stimuli cause inhibition or detrimental effects [94]. To this
regard, low levels of reactive aldehydes may modulate cell signaling, cellular proliferation and
many other processes [7,61,89,95]. A typical example is represented by 4-HNE, which may also act
as a signaling molecule by modulating the activity of different stress-related transcription factors,
such as nuclear factor-erythroid 2-related factor 2 (Nrf2), activating protein-1, NF-κB, and peroxisome
proliferator-activated receptors (PPARs) [96–100]. Moreover, low levels of 4-HNE may stimulate
the activity of protein kinase C (PKC), may increase cell proliferation, and the expression of
cyclooxygenase type 2 (COX-2) and prostaglandin E2 (PGE2) [51].
3. The Endocannabinoid System: Endocannabinoids, Their Lipid Analogues, and the Receptors
Over the last years, the ECS has attracted considerable attention as a signaling system because of
its emerging regulatory functions in health and disease.
Several components jointly make up the ECS, and they specifically consist of (1) the ECs,
endogenous bioactive lipid mediators generated in the brain and in several peripheral tissues;
(2) two membrane G-protein-coupled receptors (GPCRs) referred to as CB1 and CB2, and others,
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not yet identified, receptors; and (3) several proteins implicated in the biosynthesis, release, transport,
and degradation of these lipid mediators [101].
N-arachidonoyl-ethanolamine or anandamide (AEA) and 2-arachidonoyl-glycerol (2-AG),
both derived from the arachidonic acid, are the best characterized members of the main families
of ECs (N-acylethanolamines (NAEs) and monoacylglycerols (MAG), respectively) and exert their
biological effects by interacting with CB1 and/or CB2 receptors [102]. AEA, an endogenous eicosanoid
derivative isolated from pig brain in 1992, was the first EC to be identified [103], and it is well known
to modulate several physiological functions being present in the autonomic and in the CNS as well as
in the gastrointestinal tract and in the cardiovascular, immune and reproductive systems [104,105].
The second EC ligand to be discovered was 2-AG [106], which has been identified in brain and
reproductive tissues in higher concentrations compared to AEA [107–109]. Moreover, 2-AG has also
been found in the heart, endothelial cells and circulating cells such as macrophages and platelets [104].
Even though AEA and 2-AG interact with both CB1 and CB2 [110], they show different affinity
and efficacy. In particular, depending of on the specific tissue, AEA can be either a partial or a full
agonist of CB1, whereas it shows a low overall efficacy for CB2, for which it is a relatively weak
ligand [111]. On the contrary, 2-AG appears to be a full agonist of both receptors [112] showing higher
CB1 and CB2 efficacy than AEA.
Unlike what has been thought for many years, CB1 expression is not restricted to the brain,
where it represents the most abundant of all GPCRs [113,114], but it has been also identified, albeit at
much lower concentrations, in various peripheral tissues and cell types including adipose tissue, liver,
skeletal muscle, kidney, bone, pancreas, myocardium, human coronary artery endothelial and smooth
muscle cells and inflammatory cells (macrophages, lymphocytes) [104,115,116].
In the brain, CB1 is widely present in cerebral cortex, hippocampus, caudate-putamen,
substantia nigra pars reticulata, globus pallidus, entopeduncular nucleus, and cerebellum [117].
Interestingly, accumulating evidence supports a new mechanism of action of CB1 signalling in
the brain, since it has been found in mitochondria, where it probably modulates neuronal energy
homeostasis [118]. On the other hand, the CB2, also known as the “immune cannabinoid receptor”,
is primarily expressed in immune and hematopoietic cells. However, its presence has also been
established at lower, although functionally relevant, levels in the brain, liver, gut, exocrine and
endocrine pancreas, reproductive cells, bone, myocardium, human coronary endothelial and smooth
muscle cells, and inflammatory cells (e.g., lymphocytes, macrophages, neutrophils) [104,115,119].
CB1 and CB2 are seven-transmembrane-domain proteins both coupled with Gαi/o proteins,
which inhibit adenylyl cyclase (AC) leading to a reduced protein kinase A (PKA) and PKC activity
and to the consequent inhibition of voltage-gated Ca2+ channels and activation of inwardly rectifying
K+ currents [120]. Furthermore, through a common pathway mediated by Gαo proteins, CB1 and
CB2 are also able to modulate Ras-related protein (Rap) (a member of the Ras small G protein family)
and, in particular, it has been postulated that the activation of Gαo would release Rap1 guanosine
triphosphatase (GTPase) activating protein (Rap1 GAP), which then would be free to inhibit the activity
of Rap [121]. Moreover, several observations demonstrated that, depending on the CB1 agonist,
this receptor could also interact with Gαs proteins [122,123].
On the basis of the cell type, the signaling of CB1 and CB2 may also involve G protein independent
mechanisms, leading to the activation of mitogen-activated protein kinases (MAPKs) including
p38- and p44/42-MAPKs, c-Jun N-terminal kinase (JNK), PKA and PKC, COX-2, and ceramide
signaling [124–126].
However, beyond binding the CB1 and CB2 there is increasing pharmacological evidence
for additional receptor targets for ECs [127], such as the transient receptor potential vanilloid 1
(TRPV1) [127–129], the PPARs family [130,131] and the orphan G protein-coupled receptors 119
(GPR119), 55 (GPR55) and 18 (GPR18) [132]. TRPV1 is a member of the vanilloid transient receptor
potential cation channel subfamily, abundantly expressed in the cardiovascular system, peripheral
nervous system, CNS and in epithelial cells of the bladder and the gastrointestinal tract. It is known to
Antioxidants 2018, 7, 93 9 of 44
act by activating PKA and the endothelial nitric oxide synthase (eNOS), thus stimulating the production
of •NO and the release of calcitonin gene-related peptide and substance P [133,134], which, in turn,
lead to the altered ion permeability [135].
The finding that some pharmacological actions of AEA can be mediated by the activation of TRPV1
suggests the capability of this endogenous lipid compound to act as an “endovanilloid” [136,137],
although AEA induces typical TRPV1-mediated effects with a lower affinity compared to CB1 [127].
PPARs are a family of transcription factors constituted by three different isoforms (α, β/δ, and γ),
widely expressed in tissues with a higher oxidative capacity such as the cardiovascular system and,
in particular, cardiomyocytes, endothelial cells, and vascular smooth muscle cells [104], but also in
several brain areas and in peripheral tissues such as kidney and liver [138].
After being activated by a ligand, PPARs stimulate gene expression by creating heterodimers
with the retinoid X receptor (RXR), thereby binding to specific peroxisome proliferator response
elements (PPREs) in the promotor region of target genes [139]. They are involved in different
biological processes, such as energy homeostasis, lipid and lipoprotein metabolism, cell proliferation
and inflammation, blood pressure control and hypertensive-related complications, such as stroke and
renal damage [140,141]. Furthermore, among the different members of the PPARs family, PPAR-α is
recently attracting great attention for its anti-oxidative properties [142].
Moreover, AEA has been shown to exert anti-inflammatory and analgesic actions, and to control
feeding behavior by activating the isoform α and γ of PPARs receptors [130,143,144]. Unlike AEA,
2-AG has no affinity for TRPV1 and is only able to activate PPARs [144,145].
As above mentioned, additional GPCRs were suggested to participate in non-CB1/CB2-mediated
actions of ECs including the GPR18, GPR119 and GPR55 [146].
The GPR18, widely expressed in the cardiovascular system, CNS, spleen, and testis, is coupled
with Gαi/o proteins whose activation results in the AC inhibition and in the modulation
of the PI3K/Akt and extracellular signal-related kinases (ERK 1/2) pathways [104]. The Gαs
coupled-GPR119, primarily expressed in human and rodent pancreas, foetal liver, gastrointestinal
tract and in rodent brain, stimulates AC leading to increased intracellular adenosine 3′,5′-cyclic
monophosphate (cAMP) levels, thus regulating incretin and insulin hormone secretion [147].
Finally, the GPR55, which is expressed in human brain and liver, but also in rat spleen, vasculature,
intestine, foetal tissues, decidua, and placenta, is coupled with Gα12/13 proteins and increases
intracellular Ca2+ via the activation of RhoGTPase nucleotide exchange factors (RhoGEFs) [148].
Different from the classical neurotransmitters, the ECs are not stored in intracellular vesicles but
are synthesized “on demand” from membrane phospholipid precursors in response to stimuli that
trigger an increase in intracellular Ca2+ levels [131], and then released from postsynaptic neurons to
act on presynaptic CB1/CB2 through a retrograde mechanism [149,150]. However, recent findings
suggested that AEA could be stored inside the cell into adiposomes, which are thought to connect
plasma membrane to internal organelles along the metabolic route of this EC [151].
Although 2-AG and AEA are both derived from arachidonic acid, they do not share the same anabolic
and catabolic enzymes [126]. Depending on the available precursors and the distinct physiological or
pathological conditions [131], AEA can be synthesized by multiple routes. The main pathway for AEA
biosynthesis consists of the enzymatic cleavage of the precursor N-acyl-phosphatidylethanolamine
(NAPE), which is mediated by the NAPE-phospholipase D (NAPE-PLD) [152], whereas the
biosynthesis of 2-AG begins with the hydrolysis of 2-arachidonoyl-phosphatidylinositol that occurs
through the activity of diacylglycerol lipase (DAGL) and phospholipase Cβ [153].
ECs have a short duration of action, being rapidly metabolized by intracellular enzymes such
as fatty acid amide hydrolase (FAAH), the main enzyme responsible for AEA degradation [154–156],
and monoacylglycerol lipase (MAGL), which favors 2-AG catabolism [157].
Additional oxidative enzymes, including COX-2, LOXs and cytochrome P450 may also play a role
in the metabolism of both AEA and 2-AG by transforming them in bioactive eicosanoids [158,159],
which may activate cannabinoid receptor-independent mechanisms [160].
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Beyond the ECs, several other endogenous mediators have attracted considerable attention, despite
some of them showed poor affinity for CB1 and CB2 [126]. Among them, palmitoylethanolamide
(PEA), stearoylethanolamide (SEA), and oleoylethanolamide (OEA), belonging to the family of
NAEs, are the best characterized. However, other lipid analogues have recently been discovered
and include N-arachidonoyldopamine (NADA), Cis-9,10-octadecanoamide (oleamide or ODA),
and N-arachidonoylglycine (NAGly) [161], commonly referred to as endovanilloids because of
their ability to activate TRPV1. Additionally, 2-arachidonoylglyceryl ether (noladin ether, 2-AGE),
O-rachidonoylethanolamine (virodhamine), and arachidonoyl-L-serine (ARA-S) have also been
identified [105].
Although still debated, NAEs are generally thought to be cannabinoid-receptor inactive, and they
appeared to be responsible for enhancing AEA activity through the so-called “entourage effect”,
which consists in the inhibition of FAAH leading to an increase of AEA tissue levels [162].
PEA and OEA, shorter and fully saturated analogues of AEA, are well-documented high affinity
PPAR-α and TRPV1 endogenous ligands and have been shown to exert roles in many physiological
and pathological conditions such as satiety, inflammation, pain and memory consolidation [163–168].
Furthermore, due to their high expression in the CNS, growing evidence established their protective
effects in neurodegenerative and neuropsychiatric disorders [169–172]. Moreover, PEA is also an
endogenous agonist of GPR55, while OEA can bind GPR119.
As already mentioned, NADA belongs to the endovanilloid class of ECs and is an endogenous
ligand of CB1, TRPV1 and PPAR-γ [105]. Since this compound is widely distributed in the brain,
particularly in the striatum, hippocampus, cerebellum, and dorsal root ganglia, it has been shown to
exert a role in neuronal pain and inflammation [105]. Interestingly, NADA also showed antioxidative
and anti-inflammatory effects on glial cells [105].
2-AGE is an endogenous analogue of 2-AG, able to bind to CB1, PPAR-α and very weakly to
CB2 [143,173]. Moreover, thanks to its chemical structure, 2-AGE is more stable compared to AEA and
2-AG, which are rapidly hydrolysed in vivo [102].
Virodhamine is the ester of arachidonic acid and ethanolamine and is more expressed in
the periphery compared to the brain, where it is rapidly converted to AEA, due to its chemical
instability. Virodhamine has been shown to act as a full agonist of CB2 and a partial agonist of CB1,
whereas at higher concentrations it can be also a CB1 antagonist [174]. Furthermore, it appeared to
activate also PPAR-α [143] and GPR55 [175].
NAGly is an efficacious ligand of the orphan GPR18, with no CB1, CB2, or TRPV1 activity,
and shows analgesic, anti-inflammatory, and vasorelaxant properties [176].
AraS is another ECs-like compound structurally similar to AEA, which was demonstrated to
produce endothelium-dependent arterial vasodilatation and to activate p44/42 MAPKs in cultured
endothelial cells, effects also observed after ECs treatment [105]. To date, AraS has been shown to be a
low efficacy agonist to GPR18 without binding CB1/CB2 or additional ECs receptors [105].
Lastly, ODA is a full agonist of cannabinoid receptors with selectivity for the CB1, whose activation
is the primary responsible for ODA effects [105].
As suggested by the wide range and distribution of the cannabinoid receptors and by the several
compounds that take part in the ECS, the latter is now considered as a complex signaling system
that may play a key role in physiological and pathological conditions. Thus, targeting these intricate
pathways can represent a challenge in finding a therapeutic benefit for cannabinoid-based drugs in
various disorders.
4. Modulation of Oxidative Stress and Lipid Peroxidation through Cannabinoid Receptors by
Endocannabinoids and Their Lipid Analogues
It is well documented that there is an important cross-talk between the ECS and various
redox-dependent processes. Indeed, the ECS has been reported as a novel therapeutic target against free
radical-induced lipid peroxidation. In fact, it has been shown that ECS is implicated in the development
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of a growing number of diseases linked with redox homeostasis deregulation, including those
associated with metabolic disorders, such as type 2 diabetes and obesity, cardiovascular diseases,
as well as various neuropsychiatric and neurodegenerative disorders, ischemia/reperfusion (I/R)
injury, and renal diseases [2,4,5,54,177].
In the past decade, various and complex pathways have been studied to clarify the role of ECs in
the modulation of redox imbalance, whose knowledge is the specific aim of this review.
There is accumulating evidence that shows the ability of ECs to alter the expression and/or
the activity of enzymes implicated in the generation of these reactive small molecules (such as NOX2
and NOX4), and to modulate the production of cellular ROS/RNS by controlling mitochondrial-derived
ROS/RNS generation [177].
Alternatively, ECs and their lipid analogues may modulate oxidative stress and lipid peroxidation
either by conveying beneficial free radical scavenging effects or through targeting CB1 and CB2 [8–10].
Furthermore, CB1 and CB2 are differentially involved in oxidative stress modulation. In fact,
several studies highlight that the activation of CB1 results in a redox imbalance enhancement,
whereas CB2 stimulation is responsible for lowering ROS/RNS formation [9]. The beneficial or
detrimental effects of ECs may be cell- and injury-type-specific and may depend on the stage of
the disease progression as well [8].
This aspect was further investigated by Han and colleagues, who demonstrated a different role of
CB1 and CB2 in regulating macrophage activity, and, in particular, the former appeared to be directly
involved in the induction of intracellular ROS/RNS formation with consequent pro-inflammatory
macrophage response, while the latter, after being activated by AEA, was able to negatively regulate
CB1-stimulated ROS/RNS generation, through a pathway involving the small G protein, Rap1 [9].
The authors further showed that blocking CB1 while selectively activating CB2 might suppress
pro-inflammatory responses of macrophages.
These data are consistent with other studies using cisplatin-induced renal dysfunction [178–181],
in which it was observed that blocking the CB1 [179], or activating the CB2 [180,181], led to
the attenuation of the cisplatin-induced increase of renal 4-HNE and ROS/RNS-generating enzymes
(NOX2 and NOX4) expression, thus protecting against tubular damage.
Other examples of the opposite effects of CB1 and CB2 come from studies conducted in animal
models of obesity and type 1 and 2 diabetes mellitus, where an increase of oxidative stress is
observed [182–184]. In fact, in these models, increased levels of ECs in various renal cells contribute to
the development of oxidative stress, as a result of renal CB1 activation, whereas inhibition of CB1 or
activation of CB2 are able to ameliorate such effects (Figure 5) [185].
Overall, the over activation of the ECS that occurs in many type of tissue injury may
induce oxidative stress, inflammatory cell infiltration, and the consequent cell death through CB1
activation [8,179], while it may also serve as an endogenous compensatory mechanism to limit early
inflammatory response and interrelated oxidative stress-cell death through the activation of CB2 [186].
Interestingly, a cross-talk between redox homeostasis and ECS is particularly involved in
the regulation of the cardiovascular system and metabolic tissues (i.e., liver, skeletal muscle and
adipose tissue) [187,188], where CB1 and CB2 are widely distributed. Furthermore, previous studies
have suggested increased ECs levels in many cardiovascular disorders, such as cardiomyopathies,
atherosclerosis, and hypertension [189].
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nitrogen species (ROS/RNS) and reactive aldehydes formation. AM281: 1-(2,4-dichlorophenyl)-5-(4-
iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide; SR141716: rimonabant; CB: can
nabinoid receptors; AEA: anandamide; 2-AG: 2-arachidonoyl-glycerol; TRPV: transient receptor
potential vanilloid; CTA: crotonaldehyde; NAGly: N-arachidonoylglycine; GPR18: G protein-
coupled receptor 18; GPR55: G protein-coupled receptor 55; LPI: L-α-lysophosphatidylinositol; ECs:
endocannabinoids; PEA: palmitoylethanolamide; PPARs: peroxisome proliferator-activated receptors;
SOD: Cu2+/Zn2+-superoxide dismutase; MDA: malondialdehyde; PPRE: peroxisome proliferator
response element; RXR: retinoid X receptor; NOX: NADPH oxidase enzyme; GSH: glutathione; GSSG:
oxidized glutathione; ACR: acrolein; MAPK/ERK1/2: mitogen-activated protein kinases/extracellular
signal-regulated kinases; PKA: protein kinase A; cAMP: adenosine 3′,5′-cyclic monophosphate;
CAMKII: Ca2+/calmodulin-dependent protein kinase; AC: adenylyl cyclase.
It is well known that cardiovascular diseases are associated with oxidative stress, which leads to
the accumulation of lipid peroxidation-derived reactive aldehydes and may consequently cause an
increase in the formation of ROS/RNS and/or a decrease in the antioxidant defense [2].
In this regard, it has been demonstrated that, after being activated by AEA, CB1 expressed
in endothelial cells [190] and in cardiomyocytes in a murine model of doxorubicin-induced
cardiomyopathy [8], induce the activation of the p38-JNK-MAPK pathway and increase the generation
of ROS/RNS. These effects lead to cell death and resulted to be partially attenuated by
the pharmacological inhibition of CB1 [9].
In contrast to CB1, the activation of CB2 appeared to exert cardioprotective effects by reducing
O2•− production and decreasing endothelial cell activation. These findings are in agreement with
recent studies showing that CB2 activation, by ECs and their analogue lipid mediators, protects against
oxidative stress-induced tissue damage in experimental models of I/R injury [191–195], cardiovascular
inflammation, and/or atherosclerosis [191,196,197].
Among the cardiovascular diseases, atherosclerosis is due to altered homeostatic redox processes
with progressive ROS/RNS over production, which leads to the generation and deposition of toxic
oxidized low-density lipoproteins (oxLDL) in the vessel wall. It has been clearly demonstrated that
OxLDL promote the activation of NOXs and the synthesis of O2•− by a cluster of differentiation 36
(CD36) scavenger receptor-mediated method, effects that can be counteracted by several compensatory
mechanisms including the involvement of the ECS [198].
Support for this comes from the observation that increased production of O2•− and enhanced
NOXs activation in atherosclerosis correlated with increased rates of 2-AG biosynthesis in the vessel
wall, which may be a compensatory response to oxidative stress via CB2 signaling [199].
In agreement with these results, it has been observed that the genetic disruption of CB2 in
Apolipoprotein E-deficient mice (ApoE−/−), a murine model of atherosclerosis, is the cause of
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boosted O2•− generation, whereas its stimulation reduced vascular O2•− release, resulting in
the suppression of ROS/RNS generation and a subsequent reduction in the size of atherosclerotic
lesions (Figure 5) [200].
Further evidence of the protective effects of ECs in atherosclerosis comes from the demonstration
that CB1 inhibition in ApoE−/− mice is able to promote the down-regulation of vascular angiotensin II
type 1 receptor (AT1), which is responsible for NOXs activation when stimulated by angiotensin II [201].
Consequently, the decreased expression of AT1, mediated by CB1 inhibition, leads to the reduction of
NOXs activity and oxidative stress, thereby improving endothelial function and exerting beneficial
direct vascular effects [201].
Since the discovery that the levels of NAEs are higher in several pathological conditions linked
with redox homeostasis impairment, these compounds are attracting great attention as a survival
response toward oxidative damage [202].
Indeed, it has been clearly shown that NAEs, particularly 16:0 and 18:0, exert protective effects in
many diseases by the inhibition of free radical-induced lipid peroxidation [203], which is considered
one of the main causes of cell damage and death [204].
In particular, previous findings discovered an involvement of two long-chain NAEs, PEA and
SEA, in the inhibition of lipid peroxidation in liver mitochondria membranes of acute hypoxic
hypoxia animal model [203], a pathological condition associated with an increase in partially reduced
oxygen products, which represent the main cause of lipid oxidation-induced formation of reactive
aldehydes [205]. The authors suggested that the inhibitory effect of NAEs on lipid peroxidation
depends on the length of acyl chain and is related to their ability to protect membranes [206].
These results are in good agreement with other data showing that OEA treatment of rat heart
mitochondria is able to reduce the production of MDA, which is one of the end products of lipid
peroxidation in cell membrane [203].
Among NAEs, OEA, PEA, and AEA appeared to inhibit Cu2+-induced in vitro lipid peroxidation
in plasma lipoproteins [202] and cardiac mitochondria [207], consequently showing antioxidant
properties in the pathogenesis of atherosclerosis. Moreover, Zolese and collaborators demonstrated
that, depending on its concentration of incubation, PEA exerts both anti-oxidative and pro-oxidative
effects on radical-induced oxidation of plasma LDL [208]. The authors showed that higher PEA
concentrations could be responsible for its pro-oxidant effect, whereas PEA at lower levels is able to
suppress reactive aldehydes, generated by lipid peroxidation, and to decrease the consumption rate of
LDL endogenous anti-oxidants, thereby showing anti-oxidant properties [208].
In the context of cardiovascular diseases is also interesting to mention hypertension, which is
characterized by (1) deregulation of ECS with increased activity of FAAH and MAGL, (2) increased
levels of AEA, 2-AG, and NADA, and (3) increased expression of CB1 [209], effects that are
accompanied by an imbalance of redox homeostasis (decreased activities of glutathione peroxidase
(GPx), glutathione reductase (GR) and the antioxidant enzymes Cu2+/Zn2+-superoxide dismutase
(SOD) and catalase (CAT)).
It has been demonstrated that increased levels of AEA, following chronic administration of
the FAAH inhibitor URB597 in a rat model of hypertension [210], significantly enhanced the expression
of the CB1, thus preventing the hypertension-induced decrease of SOD, glutathione (GSH) and
glutathione transferase (GT) activities and consequently lowering ROS generation and inducing
hypotension. However, it has been postulated that the enhanced AEA levels are responsible for
the perturbation of membrane phospholipid metabolism resulting in PUFAs chain cyclization or
fragmentation. This causes an increase in the formation of α,β-unsaturated reactive aldehydes such as
4-HNE, MDA, and 4-ONE in the liver of hypertensive rats [209].
It is well documented that ECS and oxidative stress may also play a role in the pathophysiology
of liver diseases [188,211]. For instance, DeLeve and collaborators [212] reported that CB1
activation is responsible for liver inflammation and, therefore, induces non-alcoholic liver disease,
Antioxidants 2018, 7, 93 14 of 44
whereas the CB2 stimulation appeared to have protective effects in liver damage through reducing
liver oxidative stress [213].
Accumulating evidence supports the involvement of ECS as a therapeutic potential in many
neurodegenerative pathologies such as Alzheimer’s and Parkinson’s diseases, in which oxidative
stress has been recognized as one of the hallmarks of the pathology [4,171,172,214–217].
Indeed, the brain is a tissue with a high oxygen consumption whose cell membranes are
particularly rich in PUFA side-chains and, therefore, highly sensitive to lipid peroxidation and oxidative
damage [54,183,218].
NOXs enzymes have been shown to be significant sources of ROS/RNS during tissue injury
and, in particular, it has been observed that the activation of NOX2 contributes to oxidative
imbalance–induced CNS damage [219], while its inhibition is able to ameliorate cerebral oxidative
stress injury [220].
A recent study conducted by Jia and collaborators defined AEA as a promising candidate
for the treatment of oxidative stress–related neurological disorders [221]. In particular, AEA has
been found to protect a mouse hippocampal neuron cell line from H2O2-induced redox
imbalance by increasing SOD and GSH intracellular levels, reducing oxidized glutathione (GSSG),
increasing the GSH/GSSG ratio, and lowering NOX2 expression. All of these effects were completely
abolished by both CB1 antagonist administration and CB1-siRNA, suggesting that the ability of
AEA to ameliorate oxidative stress in hippocampal neurons may be mediated by CB1 activation
(Figure 5) [221].
Similarly, it has been also reported that the stimulation of CB1 is able to reduce intracellular
ROS/RNS generation and NOX2 expression thus enhancing nigrostriatal dopaminergic neurons
survival in a mouse model of Parkinson’s disease [222].
These findings supporting the beneficial effects of CB1 activation against ROS/RNS formation
in the brain seem to be controversial in comparison to what above mentioned for the cardiovascular
and renal tissues. An explanation for this argument comes from growing evidence suggesting that
the pathways underlying the interplay between cannabinoid receptors and oxidative stress modulation
may be cell type–specific [177].
Notably, as well as responses mediated by CB1, further data showed that the modulation of CB2
signaling, either by using specific CB2 agonists [223–225] or by inhibiting 2-AG degrading enzyme
MAGL [226], can ameliorate the morphological changes induced by oxidative stress and attenuate
cerebral β-amyloid plaque accumulation in a mouse model of Alzheimer’s disease carrying mutated
human APPswe and PS1dE9 genes [227,228].
Interestingly, in vitro studies revealed that a selective CB1 agonist, arachidonyl-2-chloroethylamide,
decreased the Fe2+-induced lipid peroxidation in the brain, through a metal-chelating mechanism, as well
as the •OH radicals generated by the Fenton system [229].
Moreover, the activation of the recently discovered mitochondrial CB1 by arachidonyl-2-chloroethylamide
has been demonstrated to reduce oxidative stress, thereby exerting neuroprotective effects in I/R
injury [227]. To this regard, CB2 activation also appeared to have a role in attenuating I/R damage
through lowering ROS/RNS production and lipid peroxidation [227].
The involvement of CB2 in I/R injury has also been investigated in a context of propofol
cardioprotection in an in vivo model of myocardial I/R injury, in which it has been observed that CB2
inactivation reverses propofol cardioprotective and anti-oxidative effects [230]. These findings imply
that the enhancement of ECs release and the subsequent activation of CB2 signaling are responsible for
the reduced oxidative stress mediated by propofol cardioprotection in myocardial I/R injury [230].
Furthermore, CB2 are expressed in the bladder [231] and are involved in the treatment of
hemorrhagic cystitis, a common side effect of Cyclophosphamide, an antineoplastic alkylating agent
usually metabolized by the liver to ACR, which is accumulated in urine and therefore is considered to
be the main responsible for Cyclophosphamide-induced cystitis [232]. The findings of this study
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revealed that, following stimulation, CB2 attenuated ACR-induced cystitis through modulating
ERK1/2 MAPK pathways (Figure 5) [232].
AEA and 2-AG are also involved in the progression of cancer, where they were shown to exert
protective effects against increased ROS/RNS production–induced tumor [233], leading to apoptosis
in normal and cancer cells by modulating ERK and ROS/RNS pathways [234].
5. Modulation of Oxidative Stress and Lipid Peroxidation through the Transient Receptor
Potential Vanilloid Channels by Endocannabinoids and Their Lipid Analogues
The transient receptor potential (TRP) channels superfamily is a wide group of tetrameric channels
formed by six transmembrane domains and a cation-selective pore. On the basis of its amino acid
sequence homology, TRP superfamily, in mammals, is organized into six subfamilies, which include
TRP canonical, TRP melastatin, TRP ankyrin, TRP mucolipin, TRP vanilloid, and TRP polycistin
channels. TRP channels are ubiquitously expressed in most mammalian cells [235,236] and they
depolarize cells by altering membrane potential or intracellular Ca2+ concentration. With the exception
of some TRP channels, most of them are non-selective and weakly voltage-sensitive [237]. TRP channels
are fundamental players of sensory physiology as they respond to environmental stimuli such as taste,
light, sound, smell, touch, temperature, and osmolarity [238]. Today, only a few endogenous ligands are
known to activate TRP channels, and it is not yet clear how they are activated in vivo [237]. However,
several experiments performed on knockout mice are revealing the complexity and the different
functions of TRP channels [238–240].
In this review, we will focus mainly on the vanilloid TRP (TRPV) channels subfamily and how
they respond to oxidative stress and lipid peroxidation-induced cell damage. Currently, six TRPV
channels (TRPV1-6) have been identified and divided into two subgroups: TRPV1-4 and TRPV5-6,
based on their amino acid sequence, functions, and cation selectivity. A detailed review on TRPV
channels pharmacology has been provided by Vriens and colleagues [241]. Briefly, TRPV1 is expressed
in primary sensory neurons, in few brain regions (hypothalamus, intrafascicular, supramammillary
and rostral raphe nuclei, entorhinal cortex, hippocampus, and periaqueductal gray), as well as in
smooth muscle cells of several thermoregulatory tissues (skin, dura, tongue, trachea, cremaster
muscle, and ear) [242]. TRPV1 seem to be activated by heat above 43 ◦C, by low pH [243–245],
by vanilloid compounds (e.g., capsaicin and capsinate) [243,246], by ethanol [247,248], as well as by
several endogenous compounds such as AEA [127], OEA [249], NADA [250], N-oleoyldopamine
(OLDA) [251], and arachidonic acid-derived metabolites released by LOXs [252]. Moreover, TRPV1
activity is modulated by various intracellular molecules and signals including calmodulin [253,254],
ATP [255], phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol 3,4,5-trisphosphate
(PIP3) [256], PKC [257], PKA [258], as well as protein phosphatase calcineurin [259].
Among the main functions, in addition to acting as a thermoreceptor, TRPV1 regulates the normal
functioning of urinary bladder [260], controls the gut afferent sensitivity to distension and acids [261]
and it also allows the taste perception of sodium chloride [262]. From a physiopathological point
of view, TRPV1 has a direct role in the behavioral response to ethanol [247,248,263], as well as in
inflammatory airway diseases [264]. Moreover, TRPV1 is also involved in vascular dementia as well as
in Huntington’s disease, where its activation promotes neuroprotection, increase learning and memory,
and reduce oxidative stress [265–267].
Differently, TRPV2 is a weakly Ca2+-selective channel, which seems to be activated by thermal
stimuli above 53 ◦C but not by low pH or vanilloid compounds [268]. TRPV2 is expressed in
different tissues including brain, spinal cord, spleen, and intestine, as well as in vas deferens, bladder,
heart, kidney [269], and immune cells such as monocytes and dendritic cells [270]. It is noteworthy
that TRPV2 signaling plays an important role in the endosomal pathway, where TRPV2 modulates
the fusion between endosomal membranes by releasing Ca2+ from early endosomes [271,272] as well
as in phagocytosis [273,274].
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TRPV3 is a non-selective cation channel activated by temperatures of 33–39 ◦C, which showed a
marked sensitization following repeated heat stimuli [275,276]. Moreover, TRPV3 could be activated
by several vegetable-derived molecules, such as eugenol, thymol, camphor and carvacrol [277,278].
Furthermore, other agents such as PIP2/PIP3, calmodulin, ATP, and inflammatory mediators like
histamine, bradykinin, and PGE2 are able to sensitize TRPV3 function [278–281]. Moreover, it was
hypothesized that, in rodent skin cells, heat-induced TRPV3 signaling could mediate an autonomous
response to heat stimulation, thus acting as thermoreceptors in keratinocytes [275,282]. In support
of this evidence, TRPV3 knock-out mice showed strong deficits in response to heat stimulation [277].
Likewise, TRPV4 is also activated by heat, in particular by temperatures of 27–34 ◦C, as well as by
osmotic and mechanical stimuli [283,284]. Among putative endogenous ligands, it was observed that
AEA, 2-AG, and arachidonic acid indirectly activate TRPV4 by epoxyeicosatrienoic acids released from
cytochrome P450 epoxygenases [285,286]. As for TRPV1 and TRPV3, TRPV4 activity is modulated
by PIP2/PIP3, calmodulin and ATP [287–289] and by several protein kinases, such as PKA, PKC,
Src family kinases (SFKs), and serum glucocorticoid-induced protein kinase-1 (SGK1) [290–293].
TRPV4 channels are widely expressed in epithelial cells of the renal convoluted tubule, trachea,
submucosal glands, as well as in neutrophils, in autonomic nerve fibers, in peripheral sensory ganglia,
in hair cells of the inner ear, and brain structures such as vascular organ of the lamina terminalis and
the hypothalamic median preoptic region [283,294,295]. Due to its widespread expression, TRPV4 is
involved in several physiological functions. In particular, it mediates temperature sensation in skin
keratinocytes, anterior hypothalamus, and sensory ganglia [275,283,284]. TRPV4 is also involved in
mechanosensation [296] and contribute to the normal functioning of the urinary bladder [297,298]
and pulmonary alveoli [299,300] and to the development of mechanical hyperalgesia in inflammatory
states [301].
TRPV5 and TRPV6 share a high sequence homology (74% of identity) and form highly
Ca2+-selective channels, which are not activated by heat [302–304]. As for the other TRPV family
members, the activity of TRPV5 and TRPV6 is modulated by a variety of second messengers,
including Ca2+, Mg2+, ATP, PIP2, calmodulin, and PKC [302,303,305–313]. TRPV5 is expressed in
several tissues but is mostly abundant in renal tubules, where it regulates transcellular transport and
reabsorption of Ca2+ [314]. Furthermore, TRPV5 is also involved in bone remodeling [315,316]. TRPV6
is widely expressed [305,317,318] but is mostly distributed in the intestine, kidney, and placenta, where
it respectively modulates the Ca2+ transcellular entry, reabsorption, and transfer to fetus [319–322].
Among endogenous ligands of TRPV, or endovanilloids, there are leukotriene B4
and 12-hydroperoxyeicosatetraenoic acid that belong to the eicosanoid family, produced by
lipoxygenase-mediated oxidation of PUFAs (especially arachidonic acid), which are potent activators
of TRPV1 [252,323]. Other lipid-derived mediators of TRPV are epoxyeicosatrienoic acids, such as
5′,6′-epoxyeicosatrienoic acid, which are synthesized from arachidonic acid by cytochrome P450
epoxygenases and may activate TRPV1 and TRPV4 [286,324].
As AEA is structurally similar to arachidonic acid as well as to PUFAs, it can be metabolized by
COX-2 and LOXs. In particular, COX-2 converts AEA into prostaglandin-ethanolamides, which are
endoperoxide molecules also known as prostamides [325,326]. On the other hand, LOXs convert AEA
into hydroperoxy fatty acids, such as 12- and 15-hydroperoxyeicosatetraenoylethanolamide, which are,
respectively, synthesized by 12-LOX and 15-LOX [327,328]. In guinea-pig bronchi, these oxidized lipid
mediators seem to act as TRPV1 agonists and are also responsible, at least partially, for the contractile
action of AEA [329].
Growing evidence supports a key role for TRPV, especially TRPV1, in the modulation of
oxidative stress and lipid peroxidation mediated by endocannabinoids, their lipid analogues, and other
lipid-related mediators. As known, AEA is considered an endovanilloid because of its ability to activate
TRPV1 [127,136,330]: several in vitro analyses performed on human and rat cell lines have shown
that AEA induces apoptotic effects via a TRPV1-mediated mechanism, which induces and increase in
intracellular Ca2+ levels, mitochondrial uncoupling, oxidative stress due to increased O2•− formation,
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cytochrome c release as well as calpain and caspase-3 activation [331–333]. Similarly, another in vitro
study performed on human bladder cancer T24 cells showed that TRPV1 activation by capsaicin was
correlated in a dose-dependent manner with an increase of cytosolic Ca2+ levels, with mithocondrial
membrane depolarization and a marked ROS/RNS generation, which reduced T24 cells viability
(Figure 5) [334].
Other studies showed that AEA was able to increase ROS/RNS production by targeting
TRPV1, [335,336], which lead to the activation of the Ca2+/calmodulin-dependent protein kinase
II (CAMKII), and to the upregulation of NOX5 [337–339].
Moreover, it was observed, in the human esophageal epithelial cell line Het1A, that acid-
or capsaicine-induced activation of TRPV1 leads to an increased production of intracellular
ROS/RNS levels as well as to increased ROS/RNS- or HNE-modified proteins. In the same study,
immunoprecipitation analyses of 4-HNE-stimulated Het1A cells revealed, also, that TRPV1 was
modified by 4-HNE [340]. In addition to 4-HNE, TRPV1 is directly activated by •NO, oxidants and
other chemical agents through the modification of cysteine free sulfhydryl groups [341]. Moreover,
functional assays with mutated TRPV showed that cysteine residues 553 and 558, between the fifth and
sixth transmembrane domains, are essential for •NO-induced activation of TRPV1, TRPV3, and TRPV4
and thus are potential targets of nitrosylation [342]. In addition, TRPV1 nitrosylation by •NO increased
the intracellular Ca2+ levels and thus enhanced the channel sensitivity to H+ and heat. These sensitizing
effects induced by nitrosylation of cysteine residues were further supported by the use of oxidizing
agents such as diamide and chloramine-T [343]. Furthermore, several studies reported that TRPV1 is
also responsive to other electrophilic compounds generated during oxidative stress. To this regard,
in TRPV1 channel-expressing human embryonic kidney (HEK) cells, a modest TRPV1 activation was
observed following 4-ONE treatment (100 µM) [344]. Another TRPV1 activator is CTA. In particular,
an in vitro study performed on murine cardiomyocytes incubated with CTA showed an increase in
TRPV1 and NOXs levels, in ROS/RNS formation, in apoptotic events, and a decrease in the activity of
mithocondrial proteins such as aconytase, uncoupling protein 2, and peroxisome proliferator-activated
receptor-gamma coactivator-1alpha [345].
6. Modulation of Oxidative Stress and Lipid Peroxidation through the Peroxisome
Proliferator-Activated Receptors-Alpha by Endocannabinoids and Their Lipid Analogues
Because of the high expression of PPAR-α in kidney, liver, heart, and brain, it is well documented
that the activation of these transcription factors exerts protective roles in cardiovascular as well as
renal, hepatic, and neurodegenerative diseases [138,346–349].
There is rising acknowledgment that the beneficial effects of PPAR-α stimulation could be
explained by its ability to dampen oxidative stress in several pathological conditions linked to the redox
impairment. A number of reports point to the involvement of various mechanisms through which
PPAR-α agonists can modulate antioxidants.
In particular, the identification of PPREs elements in promoter regions of CAT and SOD genes in
rat [347] additionally supported the involvement of these nuclear receptors in lowering ROS/RNS
formation and lipid peroxidation products.
Nevertheless, PPAR-α is not only involved in suppressing ROS/RNS generation, but it can
also play a role in modulating enzymes involved in ROS/RNS synthesis and/or scavenging.
Consistently, the decrease in striatal SOD expression, which resulted in the 6-hydroxydopamine
(6-OHDA)-induced Parkinson disease mouse model, was completely counteracted by PPAR-α agonists
confirming the ability of this nuclear receptor to regulate the transcription of antioxidant enzymes
(Figure 5) [138,346,350].
For instance, Diep and colleagues reported that the PPAR-α -induced suppression of oxidative
stress in cardiovascular diseases is mediated by the ability of PPAR-α activators to inhibit angiotensin
II-induced activation of NOXs in the vascular wall [348] and to increase scavenging enzymes as well.
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Among the PPAR-α ligands, ECs and their lipids analogues have been shown to play a prominent
role in affecting redox homeostasis in several oxidative stress-related pathologies, through a PPAR-α
dependent mechanism. Consistently, it has been shown that PPAR-α stimulation by PEA lowers
blood pressure and prevents hypertension-induced renal damage in hypertensive rats by inhibiting
the subunit p47phox of NOXs (a key regulatory subunit essential for NOXs functioning) [349], and by
significantly reducing the hypertension-induced increased levels of MDA in urine and renal tissues
(Figure 5) [348].
Moreover, through PPAR-α activation, PEA appeared to simultaneously enhance the antioxidant
defense by increasing SOD expression in the kidney [348], thus protecting from renal damage.
In agreement with these results, other studies further support the potential beneficial effects of
PEA activated-PPAR-α on kidney diseases [351]. For instance, it has been demonstrated that
PEA, by targeting PPAR-α, is able to prevent kidney damage induced by I/R injury through
dampening the lipid peroxidation products in the kidney, thereby leading to a reduction of neutrophil
recruitment [352].
Moreover, because of the high expression of PPAR-α and its endogenous lipid agonists in the CNS,
it has been demonstrated that PPAR-α activation can exert neuroprotective properties in several
neuropathological conditions, especially in neurodegenerative disorders [169], by modulating the redox
balance that resulted altered in these situations.
Further support for this comes from the observation that the brain areas that display the highest
PPAR-α expression exhibit an overlapping expression pattern with key enzymes involved in ROS/RNS
synthesis and/or scavenging including CAT, SOD1 and acyl-CoA oxidase 1 (ACOX1) [353–355],
whose genes are known to be under the control of PPAR-α [356,357].
Thanks to its anti-oxidative properties, PPAR-α protects against normal brain aging and regulates
the onset and progression of neurodegenerative disorders [358,359]. Interestingly, evidence suggests
that in conditions of neurodegeneration, oxidative stress itself is responsible for the induction of
PPAR-α expression. As a matter of fact, in hippocampal CA1 pyramidal cells of a transgenic
mouse model of Alzheimer’s disease, an increase in the levels of PPAR-α simultaneously with
the production of ACR and 8-hydroxy(de)oxyguanosine, which represent markers of oxidative
imbalance, was observed [360]. Such increase in hippocampal PPAR-α expression could trigger
the induction of its target genes encoding for peroxisomal membrane protein-70 (PMP70) and ACOX1,
which are involved in fatty acyl-CoA transport across peroxisomal membranes and peroxisomal
β-oxidation respectively, by evoking a compensatory response to Aβ-mediated mitochondrial insult
that occurs in early stage of Alzheimer’s disease [4–6,360].
In this context, PEA was demonstrated to protect neurons and glia from oxidative stress by
reducing MDA formation, thereby restoring a proper cellular redox state, and this effect appeared
to be PPAR-α-dependent [171,172,361,362]. It has also been established that PEA neuroprotective
effects are mediated, at least in part, through the de novo synthesis of neurosteroids (particularly
allopregnanolone), which is triggered by PPAR-α activation [362].
The abovementioned findings, coupled with a recent report demonstrating that PEA treatment
(through binding PPAR-α) is able to induce SOD and dampen ROS/RNS-induced oxidative damage
in 6-OHDA-induced mouse model of Parkinson disease, additionally suggest the neuroprotective
scavenging effects of this lipid compound (Figure 5) [363]. Beyond the ECs, several other synthetic
ligands of PPAR-α have been shown to exert antioxidative properties. For instance, Wy14643 through
binding PPAR-α is able to protect rabbit hearts from I/R injury by increasing the expression of
the oxidative stress-inducible isoform of heme oxygenase and to preserve hippocampal neurons from
H2O2 challenge by modulating mitochondrial fusion and fission events [360].
Moreover, it should be noted that the production of PPAR-α endogenous ligands, PEA and OEA
as the mostly characterized, could be differently affected by physiological and pathological oxidative
stress-related conditions. For instance, the ROS/RNS metabolism imbalance, which is responsible
for oxidative stress-induced brain aging and neurodegeneration, can quantitatively and qualitatively
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modify the production of PPAR-α agonists and thus differently modulate PPAR-α-mediated pathways
in neuronal and astroglial cells [169].
Additionally, the interplay between PPAR-α and oxidative-stress-induced lipid peroxidation
comes also from the observation that NOXs activated-4-HNE is able to act as an endogenous
PPAR-α activator leading to the discovery of the so called “lipid peroxidation products–PPARs–NOXs
axis” [364]. The regulation of this axis, which represents an alternative pathway mediating ROS/RNS
production, could ensure additional strategies to counteract oxidative-stress-related disorders.
7. Modulation of Oxidative Stress and Lipid Peroxidation through Other Receptors by
Endocannabinoids and Their Lipid Analogues
Recently, in addition to PPAR-α and TRPV1, the orphan receptors GPR18, GPR55 and GPR119
were assessed as novel cannabinoid-related receptors [365]. Structurally, GPRs are GPCRs and,
among them, GPR18, GPR55 and GPR119 share a limited primary sequence homology with
CB1 and CB2.
GPR18 was discovered for the first time in 1997 by Gantz and colleagues [366]. GPR18 is widely
expressed in testis and spleen, and in lesser extent in several other tissues such as thymus, lymph nodes,
peripheral blood leukocytes, small intestine, and appendix, thus suggesting a regulatory role for
GPR18 in the immune system [366]. Moreover, GPR18 was also found in several brain regions such
as hypothalamus, brainstem, cerebellum, and striatum as well as in lung, thyroid and ovary [367].
Several studies reported that NAGly is the endogenous ligand of GPR18 that induces an elevation
of intracellular Ca2+ levels [176]. The same authors demonstrated also that GPR18 activation was
pertussis toxin-sensitive, suggesting the involvement of a Gαi/o protein in this response [176]. Despite
these first evidence, several authors reported variable responses of GPR18 following the administration
of NAGly [368,369].
For the first time Penumarti and colleagues demonstrated that GPR18 is expressed in the rostral
ventrolateral medulla of rats and exerts tonic restraining influence on blood pressure [370]. In particular,
authors observed that the systemic administration of abnormal cannabidiol, a synthetic agonist of
GPR18, induced a dose-dependent reduction of blood pressure and increased heart rate. In addition,
GPR18 activation increased neuronal adiponectin and •NO, and finally reduced neuronal ROS/RNS
levels. These findings suggested for the first time a sympathoinhibitory role of GPR18 (Figure 5) [370].
More recently, another study confirmed that chronic GPR18 activation with its agonist abnormal
cannabidiol produced hypotension, suppressed the cardiac sympathetic dominance, and improved
left ventricular function in conscious rats [371]. In the same study, ex vivo analysis of plasma,
heart, and vascular tissues of treated rats revealed an increase in cardiac and plasmatic adiponectin
levels, an increase in aortic eNOS expression, augmented levels of vascular and serum •NO,
high levels of myocardial and plasmatic guanosine 3′,5′-cyclic monophosphate (cGMP), an increase
of myocardial Akt and ERK1/2 phosphorylation, and, more importantly, reduced myocardial
ROS/RNS formation [371]. These results suggest a protective role of GPR18 in cardiovascular diseases,
in particular highlights the possibility to consider GPR18 as a viable molecular target for developing
new antihypertensive drugs which are able to improve also the cardiac function.
Human GPR55 receptor was identified for the first time in 1999, through in silico studies, and was
subsequently cloned [372]. GPR55 receptor is widely expressed, and therefore its activity was correlated
with multiple physiological processes. In particular, GPR55 is expressed in the frontal cortex, striatum,
hippocampus, hypothalamus, cerebellum, and brainstem [372,373]. Moreover, GPR55 was also
found in peripheral organs and cells such as dorsal root ganglion [148], spleen, adrenal glands,
jejunum, ileum [373], pancreas [374], bones [375] and microglia [376]. The GPR55 pharmacology
and its downstream signaling are not yet certain. Nevertheless, some authors reported that ECs
such as AEA, 2-AG, and virodhamine can activate both etherologous and native GPR55-expressing
cells [148,273,377], while other groups reported that ECs are weak ligands [378,379], may act as partial
agonists [175], or are not able to activate GPR55 receptors [380,381]. Another open debate regards
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the ability of PEA to activate [373] or not the GPR55 receptors [148,382]. Despite the controversial
results about the ability of ECs to activate GPR55, it is well accepted that the endogenous lipid
L-α-lysophosphatidylinositol (LPI) and its analogue 2-arachidonoyl-sn-glycero-3-phosphoinositol are
endogenous ligand of GPR55 [379–382]. However, it is necessary to specify that LPI is not selective only
for GPR55 [383]. Moreover, GPR55 may also heterodimerize with other receptors, such as CB2 [384],
thus further confounding the results obtained so far.
About the mechanisms of downstream signaling, GPR55 activation was associated with an
increase of intracellular Ca2+ levels, with the activation of RhoA and ERK1/2 pathway, and with
the activation of several transcription factors, such as the nuclear factor of activated T-cells and
the cAMP response element binding protein (CREB) [380,382].
The human orphan receptor GPR119 was identified for the first time in 2003 by sequence
alignment tools analysis [385]. GPR119 is expressed mainly in pancreas and gut, in particular in β-cells
and pancreatic polypeptide-producing PP cells, where its activity modulates the glucose-dependent
insulin secretion [386,387], as well as in enteroendocrine L-cells, where it regulates the secretion of
glucagon-like peptide 1 [388,389]. GPR119 is also expressed in liver [390] and skeletal muscle [Cornall
et al., 2013]. In normal-weight and healthy patients it was observed that gut GPR119 expression rapidly
increased following acute fat exposure [391], thus suggesting a potential involvement of GPR119 in
type 2 dyabetes, metabolic disorder, and obesity.
The main endogenous ligands of GPR119 are, in order of potency, OLDA, OEA, PEA, and
AEA [392,393]. Other endogenous GPR119 agonists are 2-oleoylglycerol [394] and oleoyl-lysophosphati
dylcholine [386]. Clearly, also in this case, further studies are required to better characterize the
pharmacological profile of GPR119.
Increasing evidence suggests that ECs may regulate ROS/RNS levels and thus reactive aldehydes
formation by targeting GPR55. In this regard, Balenga and colleagues showed that GPR55 activity
modulates RhoA-dependent neutrophil migration, and it may prevent oxidative damage [395].
In particular, this study, performed on neutrophils, demonstrated that 2-AG-induced ROS/RNS
production, which was mediated by a CB2-dependent mechanism, appeared to be significantly
decreased following the co-treatment with the GPR55 agonist LPI [395]. This negative interaction
between GPR55 and CB2 was observed during neutrophil respiratory burst. Therefore, after an initial
synergism in inducing chemotaxis, GPR55 and CB2 disengaged and, by a functional repression,
GPR55 decreased CB2-induced oxidative damage by blocking CB2 downstream signaling [395].
Conversely, a recent study performed on human natural killer cells and monocytes unveiled a
proinflammatory role of GPR55 activation (Figure 5) [396], which could be potentially correlated
with an increase of ROS/RNS production and thus with oxidative stress.
8. The Role of Antioxidant System as Scavenger of ROS/RNS and Reactive Aldehydes
The “endogenous antioxidant system” relies on several enzymes, peptides, cofactors, and other
molecules that are essential for the maintenance of a physiological redox homeostasis. Overall,
endogenous antioxidants may be divided into two main groups, formed by enzymatic and
non-enzymatic antioxidants [6,397]. The enzymatic group include CAT [398], SOD [399,400], GPx,
GR, GT [401], thioredoxin (Trx) and thioredoxin reductase (TrxR) [402] while the non-enzymatic
group include several antioxidant molecules such as GSH, GSSG, [403], vitamin A (retinol) [404],
vitamin C (L-ascorbic acid) [405], vitamin E (tocopherols) [406], coenzyme Q10 (CoQ10) [407],
carotenoids [408], flavonoids, polyphenols [409–411], minerals such as Se2+ [412], Cu2+, and Zn2+ [413],
as well as metabolites such as uric acid, bilirubin [414] and melatonin [415], which also possess
antioxidant properties.
Briefly, CATs are Cu2+/Zn2+-dependent enzymes present in peroxisomes that catalyze
the conversion of H2O2 in water and oxygen [398]. Among SOD enzymes, cytolosic SOD are
Cu2+/Zn2+-dependent enzymes, while mitochondrial SODs are Mn2+-dependent enzymes that
metabolize O2•− into H2O2 and oxygen. Therefore, SOD represents the first line of defense against
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reactive aldehydes formation [400]. GPx, GR and GT are Se2+-dependent enzymes that, together with
GSH and GSSG, constitute the glutathione system, which contributes to eliminate H2O2 and other
reactive molecules [403]. Similarly, Trx, TrxR, and NADPH constitute the thioredoxin system, which is
critical for redox regulation of protein function and signaling via thiol redox control [402].
Vitamin A is produced in the liver, derives from β-carotene and acts as a lipid peroxidation blocker
by preventing the chaining process in the propagation phase [404]. Similarly, also vitamin E acts as a
lipid peroxidation blocker by donating a hydrogen atom to peroxyl radicals, thus forming tocopheroxyl
radicals which are unable to continue the propagation phase of lipid peroxidation [416]. Vitamin C
is effective in scavenging several ROS/RNS as well as in the detoxification of peroxyl and hydroxyl
radicals [405]. CoQ10 is involved in the neutralization of the damages induced by peroxyl radicals and
also in the regeneration of vitamin E [407]. Uric acid is known to prevent protein nitrosylation, as well
as lipid and protein peroxidation, and therefore it is considered as a protectant agent of the CNS [417].
Melatonin is a natural scavenger derived from tryptophan, which is involved in the neutralization
of several ROS/RNS and thus reduces the generation of reactive aldehydes [415]. Finally, flavonoids
and polyphenols are ubiquitous plant-derived molecules, which act as chelators and scavengers of
ROS/RNS as well as of hydroxyl and peroxyl radicals [418,419].
9. Conclusions
Oxidative stress represents an underlying disturbance that is involved in many pathophysiological
conditions. Increasing evidence suggests that tissues with a high oxygen consumption, such as brain
and heart among others, are particularly sensitive to lipid peroxidation products and free radical
accumulation, which are responsible for oxidative stress–induced damages with consequent cell
death [2,4–6,218].
Thus, acting on the cellular processes that suppress the generation of these reactive small
molecules or altering the expression and/or activity of enzymes involved in their formation may be
crucial for the treatment of a growing number of diseases linked with redox homeostasis deregulation.
In this scenario, there is rising acknowledgment about a cross-talk between the ECS and
various redox-dependent processes. Indeed, it has been observed that the redox impairment induces
the enhancement of AEA and 2-AG levels, as a consequence of phospholipid hydrolysis [420,421],
and the upregulation of CB1 and CB2 expression [422,423], as well as the downregulation of
FAAH [422].
A large number of reports point to the involvement of ECs and their lipid analogues in
regulating ROS/RNS and reactive aldehydes generation through targeting CB1 and CB2 [8–10]
and thereby exerting protective effects in cardiovascular as well as renal, hepatic, neuropsychiatric,
and neurodegenerative diseases.
Moreover, it has been observed that, depending on the type of cell and/or injury, cannabinoid
receptors show opposite effects in oxidative stress modulation, since CB1 activation results in a redox
imbalance enhancement, while CB2 stimulation is responsible for lowering oxidative stress [9,223] and
may convey beneficial free radical scavenging effects.
Overall, the mechanisms by which CB2 receptors, following ECs-mediated activation, are involved
in the reduction of oxidative injury seem to be primarily mediated by the reduction of NOX2 and
NOX4, and the simultaneous induction of the antioxidant defense through the increase of the SOD
scavenging enzymes [180,181].
Emerging evidence indicates that the neuroprotective, cardioprotective and renoprotective
effects of ECs and NAEs are additionally mediated by CB1/CB2-independent mechanisms and
involve the contribution of alternative intracellular targets such as PPAR-α, TRPV1, GPR55,
and GPR18 [169,348,349,370,371,395].
In particular, an interplay between PPAR-α and oxidative stress has been suggested from
the observation that an imbalance in the redox state may modulate several signaling pathways,
including PPAR-α signaling, via transcriptional regulation and post-translational modification.
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Among the PPAR-α ligands, PEA appeared to exert beneficial effects by simultaneously enhancing
the antioxidant defense through the increase of SOD expression and inhibiting NOXs activity with a
consequent reduction of the lipid peroxidation products such as MDA [138].
Although the huge amount of knowledge has been gained about the effects of the ECs on oxidative
stress and lipid peroxidation in several pathological conditions, many ECS compounds fail during
clinical trials due to inefficacy or unforeseeable safety concerns. For the treatment of the cardiovascular
diseases, for instance, no cannabinoid-based drugs have been approved so far, except for those acting
as PPARs agonists [348]. Among the limitations that play a role in restricting the translation of ECs
studies into clinical trials, the different animal paradigms as well as the route of administration used
(central vs peripheral) and the differences between species seem to be primarily involved.
Moreover, most of the studies have focused on the role of CB1, CB2, TRPV1, PPARs and less is
known about other candidates such as GPR18, GPR55 and GPR119.
Despite promising goals have been achieved over the last years on ECS research, there is an
urgent necessity to expand the knowledge on the ECs complex signalling in order to better identify an
explanation of the serious side-effects observed in clinical studies. Lessons from clinical experience
should encourage the scientific community to better clarify how to modulate the ECS thus leading to
major breakthroughs in the treatment of many diseases.
Overall, the findings discussed in this review may further elucidate the complex interaction
existing between ECS, oxidative stress, and lipid peroxidation, resulting in a better understanding of
the multiple beneficial effects of this signaling system in several pathological conditions related to a
redox status impairment.
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receptor type 1; CB2 = cannabinoid receptor type 2; CD36 = cluster of differentiation 36; CGD = chronic
granulomatous disorder; cGMP = guanosine 3′,5′-cyclic monophosphate; CNS = central nervous system;
CoQ10 = coenzyme Q10; COX-2 = cyclooxygenase type 2; COXs = cyclooxygenases; CREB = cAMP response
element binding protein; CTA = crotonaldehyde; DAGL = diacylglycerol lipase; dG = deoxyguanosine; ECS
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glutathione; GT = glutathione transferase; GTPase = guanosine triphosphatase; H2O2 = hydrogen peroxide;
HClO = hypochlorous acid; HEK = human embryonic kidney; I/R = ischemia/reperfusion; JNK = c-Jun
N-terminal kinase; LOXs = lipooxygenases; LPI = L-α-lysophosphatidylinositol; MAG = monoacylglycerols;
MAGL = monoacylglycerol lipase; MAPKs = mitogen-activated protein kinases; MAPK/ERK1/2 =
mitogen-activated protein kinases/extracellular signal-regulated kinases; MDA = malondialdehyde; NADA
= N-arachidonoyldopamine; NAEs = N-acylethanolamines; NAGLy = N-arachidonoylglycine; NAPE =
N-acyl-phosphatidylethanolamine; NAPE-PLD = NAPE-phospholipase D; NF-κB = nuclear factor-κB; NO2
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phosphatidylinositol 3,4,5-trisphosphate; PKA = protein kinase A; PKC = protein kinase C; PMP70 = peroxisomal
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membrane protein-70; PPARs = peroxisome proliferator-activated receptors; PPRES = peroxisome proliferator
response elements; PUFAs = polyunsatured fatty acids; Rap = Ras-related protein; Rap1GAP = Rap1 GTPase
activating protein; RhoGEFs = RhoGTPase nucleotide exchange factors; ROS/RNS = reactive oxygen and nitrogen
species; RXR = retinoid X receptor; SEA = stearoylethanolamide; SFKs = Src family kinases; SGK1 = serum
glucocorticoid-induced protein kinase-1; SOD = superoxide dismutase; TRP = transient receptor potential; TRPV
= transient receptor potential vanilloid; TRPV1 = transient receptor potential vanilloid 1; Trx = thioredoxin; TrxR =
thioredoxin reductase.
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